Selitrectinib, a selective TRK inhibitor; repotrectinib, an ALK/ROS1/pan-TRK inhibitor; and taletrectinib, an NTRK and ROS1 inhibitor, are undergoing evaluation of NTRK-positive NSCLC, with the need to further understand the impact on CNS metastases [139]. Here, ALK is linked to non-small cell lung carcinoma.